Our results showed clearly that knock out CD276 lead to a broad alteration of associated signaling and tumor promoting roles in TAMs, including downregulations of MerTK/AXL and efferocytosis, indicating a broader application scenario in cancer immunotherapy and lower possibilities of drug resistance. The gene discussed is CD276; the disease is neoplasm.